PFA Pension Forsikringsaktieselskab Invests $7.35 Million in Labcorp Holdings Inc. $LH

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position in Labcorp, buying 29,051 shares in Q4 worth approximately $7.35 million, in a stock where about 95.9% is held by institutional investors.
• Labcorp beat quarterly estimates with $4.25 EPS (vs. $4.09) and $3.54B revenue, issued FY2026 guidance of $17.70–$18.35 EPS, and holds a consensus analyst price target of $308 with a "Moderate Buy" rating.
• The company announced a quarterly dividend of $0.72 (annualized $2.88, ~1.1% yield), while insiders have recently sold shares—including CEO Adam Schechter's 8,705-share sale—with 16,113 shares sold in the last 90 days.

PFA Pension Forsikringsaktieselskab acquired a new position in Labcorp Holdings Inc. (NYSE:LH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 29,051 shares of the medical research company's stock, valued at approximately $7,352,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LH. JPL Wealth Management LLC bought a new position in shares of Labcorp in the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp in the 4th quarter valued at $26,000. Motco acquired a new position in shares of Labcorp during the 3rd quarter worth $32,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the fourth quarter worth about $29,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock valued at $35,000 after purchasing an additional 40 shares in the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Stock Down 1.1%

Shares of NYSE:LH opened at $252.99 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp Holdings Inc. has a 52-week low of $239.67 and a 52-week high of $293.72. The business's 50 day simple moving average is $270.69 and its two-hundred day simple moving average is $267.33. The firm has a market cap of $20.79 billion, a P/E ratio of 22.41, a PEG ratio of 1.72 and a beta of 0.91.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the previous year, the company posted $3.84 earnings per share. The company's quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, research analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp's dividend payout ratio is currently 25.51%.

Insider Buying and Selling

In other news, EVP Jonathan C. Meltzer sold 87 shares of the firm's stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. This trade represents a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of Labcorp stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Evercore reiterated an "outperform" rating and set a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Piper Sandler raised their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. increased their price objective on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Weiss Ratings raised shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Labcorp currently has a consensus rating of "Moderate Buy" and a consensus price target of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.